Traditionally, the interaction of G protein-coupled receptors has been described by models that assume that the receptor exists as a monomer coupled to G protein in a 1:1 stoichiometry.
However, these classical models of receptor/G protein coupling may be oversimplified. It has now been shown that many G protein-coupled receptors can form dimers or higher order oligomers and that this phenomenon has relevance to receptor function (for review, see Ref. 6 ). Dopamine receptors have also been shown to form dimers and higher order oligomers. Evidence has been provided for D 1 , D 2 and D 3 homodimers in transfected cell lines (7) (8) (9) , and D 2 receptors have been shown to exist as dimers in human and rat brain tissues (10) . Moreover, Rocheville et al. (11) has recently shown that the dopamine D 2 receptors not only form homodimers, but also form heterodimers with somatostatin SSTR 5 receptors. In addition, Gines et al. (12) have shown that the dopamine D 1 receptor forms heterooligomers with the adenosine A 1 receptor.
As the issue of G protein-coupled receptor homo-and heterodimerization is becoming more and more important, it is crucial to define the mechanism(s) of receptor-receptor interactions in order to predict which receptors can interact with one another. The results obtained until now suggest that more than one mechanism exists and that one receptor can interact with another in more than one way.
One of the mechanisms that have been proposed to explain receptor dimerization is the phenomenon of domain swapping proposed by Gouldson et al. (13, 14) . Domain swapping is a very efficient method for forming dimers, as the interactions within the monomers are being preserved in the dimer. We have previously shown that this mechanism occurs between two chimeras of α 2 -adrenergic and m 3 -muscarinic receptors (15) ; more recently, using a pharmacological approach, we by guest on November 4, 2016 http://www.jbc.org/ Downloaded from have shown that domain swapping also occurs between the wild type m 2 -and m 3 -muscarinic receptors (16) .
Since different dopamine receptors (including D 2 and D 3 ) are often physiologically coexpressed in the same cells (17, 18), we decided to use this same domain swapping approach to identify the interaction between the D 2 -and D 3 -dopamine receptors. As mentioned above, these two receptors belong to the family of D 2 -like receptors, and they share a high degree of amino acid homology, and are therefore suitable for an interaction through domain swapping.
We have previously shown that the dopamine D 2 receptor can be split at the level of the third cytoplasmic loop into two fragments (D 2trunk and D 2tail ) and that the mixture of the two fragments retains the binding and functional activity of the wild type receptor (19) . In the present study, we extended this analysis to the D 3 receptor and in addition, we cross-cotransfected the fragments originating from the two dopamine receptors in order to study the pharmacology of the Descriptions of the cDNAs for rabbit AC-V in pXMD1 and rat AC-VI in pCMV-neo were given previously (21) . The cDNA encoding the AC-V/VI chimera was prepared in pXMD1 by joining the cDNA encoding amino acids 1-856 of rabbit AC-V with that encoding amino acids 774-1166 of rat AC-VI at an AflIII site. The junction was made at an area of homology between AC-V and AC-VI in the carboxy part of the ninth transmembrane domain of the AC molecules.
Cell cultures and transfection-COS-7 cells were incubated at 37°C in a humidified atmosphere (containing 5% CO 2 ) and grown in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin. Cells were seeded at a density of 2 x 10 6 per 100-mm dish, and 24 h later, transiently transfected with the plasmid DNA encoding the dopamine receptors and, when indicated, also AC types V and VI, by the DEAEdextran chloroquine method (22) . The total amount of DNA used for each transfection was ascorbic acid. The bound ligand was separated from the unbound ligand using glass-fiber filters (Whatmann, GF/B) with a Brandel Cell Harvester, and the filters were counted with a scintillation β-counter.
AC assay-Twenty-four h after transfection, the cells were trypsinized and recultured in 24-well plates, and after an additional 24 h, the cells were assayed for AC activity. The assay was performed Immunoprecipitation and immunoblotting-Immunopreceipitation and immunoblotting were carried out essentially as described by Karpa et al. (24) . Briefly, FLAG-tagged human D 2 and HAtagged monkey D 3 dopamine receptors were expressed either singly or together in HEK 293 cells.
Immunoprecipitation was carried out using anti-HA antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA) and immunocomplexes captured using Protein A/G resin (CytoSignal, Irvine, CA).
Following separation on SDS polyacrylamide gels and transfer to nitrocellulose filters, proteins were detected using the anti-FLAG M2 monoclonal antibody (Sigma) and HRP-conjugated goat anti-mouse secondary antibodies (Jackson ImmunoResearch, West Grove, PA).
RESULTS
We had previously shown that the dopamine D 2 receptor can be split at the level of the third cytopolasmic loop and retains its pharmacological and functional characteristics (19) . (Table 2 ). As control, we showed that expression of the truncated muscarinic m 2 receptor, m 2trunk , did not modify expression of full-length dopamine D 2 or D 3 receptors (Table 2 ).
In the second part of the work, we tested whether agonist activation of the split dopamine receptors has the ability to regulate the activity of AC and thus to inhibit the FS-induced increase in cAMP production. For this purpose, we cotransfected COS-7 cells with dopamine receptors, together with AC-V. As shown in (Fig. 2B) .
We also tested the efficacy of 7-OH-DPAT to inhibit AC-VI via activation of the various dopamine receptors. In cells transiently transfected with the D 3 receptor, 7-OH-DPAT was not able to inhibit AC-VI (see Fig. 3 and Table 3 ). Conversely, the activation of all the other receptors, i.e. (Table 3 and Fig. 3 ).
The calculated IC 50 s were similar to those observed with AC-V, but the extents of inhibition were inhibit AC-VI activity. As described in Table 3 and Table 3 ). This change in AC-VI regulation when D 3 is cotransfected with D 2 suggests that a (Fig. 5, lanes 1 and 3) . Under our conditions for transfection and immunoprecipitation, we found that ~17% (± 1.53%; n=3) of FLAG-tagged D2L receptors were coimmunoprecipitated with the HA-tagged D3 receptors (data not shown).
Similar to the long form, the short form of the D 2 receptor, was immunoprecipitated together with the D 3 receptor (Fig. 5, line 5) . Treatment of transfected cells with 10 µM dopamine appeared to decrease the level of D 2 /D 3 heterodimers that were detectable by coimmunoprecipitation (Fig. 5, lane 2).
DISCUSSION
In a previous paper, we showed that the dopamine D 2 receptor can be split at the level of the third cytoplasmic loop and retain its binding and functional activity. In this paper, we have extended this analysis to the dopamine D 3 receptor and tested the ability of fragments originating from the two receptors to interact with one another. We find that fragments of the D 3 receptor are able to fully reconstitute the binding activity and the selectivity observed for the wild type D3 receptor.
These data clearly indicate that the integrity of the third cytoplasmic loop is not important, at least when the receptor is on the membrane, to maintain correct folding and function of the dopamine receptors. Rather, as shall be discussed below, it is likely that the integrity of this loop is needed for This phenomenon has been previously described in experiments in which wild type receptors were cotransfected with homologous truncated receptor fragments (24, 33, 34) . In conclusion, our data indicate that wild type dopamine D 2 and D 3 receptors can interact with each other to form a functional heterodimer that exhibit unique functional properties.
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